Skip to main navigation
Skip to content
Skip to content
PDL Logo Blue Green
  • About PDL
  • Leadership
  • Investor Relations
  • About PDL
    • Management
  • Portfolio of Assets
  • Investor Relations
  • News
  • Contact

Press Releases

PDL  > Investor Relations > Press Releases

Press Releases

  • Summary TogglePDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
    RENO, Nev. , Dec. 14, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps").  Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than
    Dec 14, 2020
  • Summary TogglePDL Announces Timeline for Voluntarily Delisting from Nasdaq
    Expects to File a Certificate of Dissolution on January 4, 2021 Trading in PDL's Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020 INCLINE VILLAGE, Nev. , Dec. 8, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that
    Dec 8, 2020
  • Summary TogglePDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
    - Consummated critical monetization transactions during third quarter, including the sale of its Noden pharmaceutical business and of a basket of royalties to SWK Holdings. Also entered into a settlement agreement with Wellstat. Subsequently completed the spin-off of its medical device company,
    Nov 11, 2020
  • Summary TogglePDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update
    Conference Call to Wednesday, November 11 at 4:30 p.m. Eastern Time INCLINE VILLAGE, Nev. , Nov. 6, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference
    Nov 6, 2020
  • Summary TogglePDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020
    INCLINE VILLAGE, Nev. , Oct. 29, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020 , on Monday, November 9, 2020 after market close.
    Oct 29, 2020
  • Summary TogglePDL BioPharma Completes Spin-Off of LENSAR
    INCLINE VILLAGE, Nev. , Oct. 2, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR").
    Oct 2, 2020
  • Summary TogglePDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020
    Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020   Conference call with slide presentation today beginning at 4:30 p.m. Eastern time INCLINE VILLAGE, Nev. , Sept. 10, 2020 /PRNewswire/ --  PDL BioPharma, Inc.
    Sep 10, 2020
  • Summary TogglePDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital
    INCLINE VILLAGE, Nev. , Sept. 9, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively " Noden ") to Stanley Capital .
    Sep 9, 2020
  • Summary TogglePDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
    INCLINE VILLAGE, Nev. , Aug. 31, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella ® , Zalviso ® , and Coflex ® (collectively the "Royalties") to SWK
    Aug 31, 2020
  • Summary TogglePDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024
    INCLINE VILLAGE, Nev. , Aug. 28, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021 Notes, the
    Aug 28, 2020
  • Summary TogglePDL BioPharma Announces Filing of a Form 10 Registration Statement with the Securities and Exchange Commission for a Potential Spin-off of LENSAR to PDL's Stockholders
    INCLINE VILLAGE, Nev. , Aug. 26, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that its majority owned medical device subsidiary, LENSAR, Inc. (" LENSAR "), has filed a registration statement on Form 10 with the Securities and Exchange Commission
    Aug 26, 2020
  • Summary TogglePDL BioPharma Enters Into Settlement Agreement with Wellstat
    INCLINE VILLAGE, Nev. , Aug. 12, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC ) (" Wellstat
    Aug 12, 2020
  • Summary TogglePDL BioPharma Reports 2020 Second Quarter Financial Results
    - Accomplished Important Asset Monetization Milestones with the Distribution of Evofem Biosciences Shares to PDL Stockholders and the Anticipated Sale of Noden to Stanley Capital   - Announced the Filing of a Form 10 with SEC for Potential Spin-off of LENSAR   - Continues to Seek Potential
    Aug 6, 2020
  • Summary TogglePDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020
    INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020 , on Thursday, August 6, 2020 , after market close.
    Jul 30, 2020
  • Summary TogglePDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital
    INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively " Noden ")
    Jul 30, 2020

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

    Investor Relations

    • Frequently Asked Questions (FAQ)
    • Investor Updates
    • Press Releases
    • 2020 Proxy Statement
    • Tax Information
      • Common Stock Tax Information
      • Convertible Note Tax Information
    • SEC Filings
    • Contact Information

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • RSS
    • Print
    • Share
    • Search
    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

PDL Logo White Fill

  • Terms of Use
  • Sitemap
© Copyright 2021 PDL BioPHARMA. All Rights Reserved.